4/15
07:10 am
atha
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer [Yahoo! Finance]
High
Report
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer [Yahoo! Finance]
4/15
07:00 am
atha
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
High
Report
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
4/11
07:22 am
atha
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease [Yahoo! Finance]
Medium
Report
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease [Yahoo! Finance]
4/11
07:00 am
atha
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Medium
Report
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
4/3
07:09 am
atha
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
4/3
07:00 am
atha
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Low
Report
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
3/29
11:59 am
atha
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
3/8
07:12 am
atha
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference [Yahoo! Finance]
High
Report
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference [Yahoo! Finance]
3/8
07:00 am
atha
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
High
Report
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
2/28
01:30 pm
atha
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]
Low
Report
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]
2/22
04:11 pm
atha
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates [Yahoo! Finance]
Low
Report
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates [Yahoo! Finance]
2/22
04:05 pm
atha
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Neutral
Report
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
2/8
04:11 pm
atha
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) [Yahoo! Finance]
Medium
Report
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) [Yahoo! Finance]
2/8
04:02 pm
atha
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Medium
Report
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
1/22
06:15 am
atha
With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors [Yahoo! Finance]
Medium
Report
With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors [Yahoo! Finance]